{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:13:41Z","timestamp":1791335621476,"version":"4.3.1"},"reference-count":33,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"31","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2017,11,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>LUME-Meso is a phase II\/III randomized, double-blind trial designed to assess efficacy and safety of nintedanib plus chemotherapy as first-line treatment of malignant pleural mesothelioma (MPM). Phase II results are reported here.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>Chemotherapy-na\u00efve patients with unresectable, nonsarcomatoid MPM (Eastern Cooperative Oncology Group performance status 0 to 1), stratified by histology (epithelioid or biphasic), were randomly assigned in a 1:1 ratio to up to six cycles of pemetrexed and cisplatin plus nintedanib (200 mg twice daily) or placebo followed by nintedanib plus placebo monotherapy until progression. The primary end point was progression-free survival (PFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eighty-seven patients were randomly assigned. The median number of pemetrexed and cisplatin cycles was six; the median treatment duration for nintedanib was 7.8 months and 5.3 months for placebo. Primary PFS favored nintedanib (hazard ratio [HR], 0.56; 95% CI, 0.34 to 0.91; P = .017), which was confirmed in updated PFS analyses (HR, 0.54; 95% CI, 0.33 to 0.87; P = .010). A trend toward improved overall survival also favored nintedanib (HR, 0.77; 95% CI, 0.46 to 1.29; P = .319). Benefit was evident in epithelioid histology, with a median overall survival gain of 5.4 months (HR, 0.70; 95% CI, 0.40 to 1.21; P = .197; median [nintedanib v placebo], 20.6 months v 15.2 months) and median PFS gain of 4.0 months (HR, 0.49; 95% CI, 0.30 to 0.82; P = .006; median [nintedanib v placebo], 9.7 v 5.7 months). Neutropenia was the most frequent grade \u2265 3 adverse event (AE; nintedanib 43.2% v placebo 12.2%); rates of febrile neutropenia were low (4.5% in nintedanib group v 0% in placebo group). AEs leading to discontinuation were reported in 6.8% of those receiving nintedanib versus 17.1% of those in the placebo group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Addition of nintedanib to pemetrexed plus cisplatin resulted in PFS improvement. AEs were manageable. The clinical benefit was evident in patients with epithelioid histology. The confirmatory phase III part of the study is ongoing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.2017.72.9012","type":"journal-article","created":{"date-parts":[[2017,9,11]],"date-time":"2017-09-11T15:59:18Z","timestamp":1505145558000},"page":"3591-3600","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":118,"title":["Nintedanib Plus Pemetrexed\/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial"],"prefix":"10.1200","volume":"35","author":[{"given":"Federica","family":"Grosso","sequence":"first","affiliation":[{"name":"Federica Grosso, Azienda Ospedaliera SS Antonio e Biagio General Hospital, Alessandria; Silvia Novello and Giorgio Scagliotti, L\u2019universit\u00e0 di Torino, Azienda Sanitaria Ospedale San Luigi Gonzaga, Turin, Italy; Anna K. Nowak, University of Western Australia, Crawley, and Sir Charles Gairdner Hospital, Nedlands, Western Australia; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia; Sanjay Popat, The Royal Marsden Hospital National Health Service ..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Steele","sequence":"additional","affiliation":[{"name":"Federica Grosso, Azienda Ospedaliera SS Antonio e Biagio General Hospital, Alessandria; Silvia Novello and Giorgio Scagliotti, L\u2019universit\u00e0 di Torino, Azienda Sanitaria Ospedale San Luigi Gonzaga, Turin, Italy; Anna K. Nowak, University of Western Australia, Crawley, and Sir Charles Gairdner Hospital, Nedlands, Western Australia; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia; Sanjay Popat, The Royal Marsden Hospital National Health Service ..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Novello","sequence":"additional","affiliation":[{"name":"Federica Grosso, Azienda Ospedaliera SS Antonio e Biagio General Hospital, Alessandria; Silvia Novello and Giorgio Scagliotti, L\u2019universit\u00e0 di Torino, Azienda Sanitaria Ospedale San Luigi Gonzaga, Turin, Italy; Anna K. Nowak, University of Western Australia, Crawley, and Sir Charles Gairdner Hospital, Nedlands, Western Australia; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia; Sanjay Popat, The Royal Marsden Hospital National Health Service ..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna K.","family":"Nowak","sequence":"additional","affiliation":[{"name":"Federica Grosso, Azienda Ospedaliera SS Antonio e Biagio General Hospital, Alessandria; Silvia Novello and Giorgio Scagliotti, L\u2019universit\u00e0 di Torino, Azienda Sanitaria Ospedale San Luigi Gonzaga, Turin, Italy; Anna K. Nowak, University of Western Australia, Crawley, and Sir Charles Gairdner Hospital, Nedlands, Western Australia; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia; Sanjay Popat, The Royal Marsden Hospital National Health Service ..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Popat","sequence":"additional","affiliation":[{"name":"Federica Grosso, Azienda Ospedaliera SS Antonio e Biagio General Hospital, Alessandria; Silvia Novello and Giorgio Scagliotti, L\u2019universit\u00e0 di Torino, Azienda Sanitaria Ospedale San Luigi Gonzaga, Turin, Italy; Anna K. Nowak, University of Western Australia, Crawley, and Sir Charles Gairdner Hospital, Nedlands, Western Australia; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia; Sanjay Popat, The Royal Marsden Hospital National Health Service ..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Greillier","sequence":"additional","affiliation":[{"name":"Federica Grosso, Azienda Ospedaliera SS Antonio e Biagio General Hospital, Alessandria; Silvia Novello and Giorgio Scagliotti, L\u2019universit\u00e0 di Torino, Azienda Sanitaria Ospedale San Luigi Gonzaga, Turin, Italy; Anna K. Nowak, University of Western Australia, Crawley, and Sir Charles Gairdner Hospital, Nedlands, Western Australia; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia; Sanjay Popat, The Royal Marsden Hospital National Health Service ..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"John","sequence":"additional","affiliation":[{"name":"Federica Grosso, Azienda Ospedaliera SS Antonio e Biagio General Hospital, Alessandria; Silvia Novello and Giorgio Scagliotti, L\u2019universit\u00e0 di Torino, Azienda Sanitaria Ospedale San Luigi Gonzaga, Turin, Italy; Anna K. Nowak, University of Western Australia, Crawley, and Sir Charles Gairdner Hospital, Nedlands, Western Australia; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia; Sanjay Popat, The Royal Marsden Hospital National Health Service ..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha B.","family":"Leighl","sequence":"additional","affiliation":[{"name":"Federica Grosso, Azienda Ospedaliera SS Antonio e Biagio General Hospital, Alessandria; Silvia Novello and Giorgio Scagliotti, L\u2019universit\u00e0 di Torino, Azienda Sanitaria Ospedale San Luigi Gonzaga, Turin, Italy; Anna K. Nowak, University of Western Australia, Crawley, and Sir Charles Gairdner Hospital, Nedlands, Western Australia; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia; Sanjay Popat, The Royal Marsden Hospital National Health Service ..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Reck","sequence":"additional","affiliation":[{"name":"Federica Grosso, Azienda Ospedaliera SS Antonio e Biagio General Hospital, Alessandria; Silvia Novello and Giorgio Scagliotti, L\u2019universit\u00e0 di Torino, Azienda Sanitaria Ospedale San Luigi Gonzaga, Turin, Italy; Anna K. Nowak, University of Western Australia, Crawley, and Sir Charles Gairdner Hospital, Nedlands, Western Australia; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia; Sanjay Popat, The Royal Marsden Hospital National Health Service ..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Taylor","sequence":"additional","affiliation":[{"name":"Federica Grosso, Azienda Ospedaliera SS Antonio e Biagio General Hospital, Alessandria; Silvia Novello and Giorgio Scagliotti, L\u2019universit\u00e0 di Torino, Azienda Sanitaria Ospedale San Luigi Gonzaga, Turin, Italy; Anna K. Nowak, University of Western Australia, Crawley, and Sir Charles Gairdner Hospital, Nedlands, Western Australia; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia; Sanjay Popat, The Royal Marsden Hospital National Health Service ..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Planchard","sequence":"additional","affiliation":[{"name":"Federica Grosso, Azienda Ospedaliera SS Antonio e Biagio General Hospital, Alessandria; Silvia Novello and Giorgio Scagliotti, L\u2019universit\u00e0 di Torino, Azienda Sanitaria Ospedale San Luigi Gonzaga, Turin, Italy; Anna K. Nowak, University of Western Australia, Crawley, and Sir Charles Gairdner Hospital, Nedlands, Western Australia; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia; Sanjay Popat, The Royal Marsden Hospital National Health Service ..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens Benn","family":"S\u00f8rensen","sequence":"additional","affiliation":[{"name":"Federica Grosso, Azienda Ospedaliera SS Antonio e Biagio General Hospital, Alessandria; Silvia Novello and Giorgio Scagliotti, L\u2019universit\u00e0 di Torino, Azienda Sanitaria Ospedale San Luigi Gonzaga, Turin, Italy; Anna K. Nowak, University of Western Australia, Crawley, and Sir Charles Gairdner Hospital, Nedlands, Western Australia; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia; Sanjay Popat, The Royal Marsden Hospital National Health Service ..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Socinski","sequence":"additional","affiliation":[{"name":"Federica Grosso, Azienda Ospedaliera SS Antonio e Biagio General Hospital, Alessandria; Silvia Novello and Giorgio Scagliotti, L\u2019universit\u00e0 di Torino, Azienda Sanitaria Ospedale San Luigi Gonzaga, Turin, Italy; Anna K. Nowak, University of Western Australia, Crawley, and Sir Charles Gairdner Hospital, Nedlands, Western Australia; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia; Sanjay Popat, The Royal Marsden Hospital National Health Service ..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"von Wangenheim","sequence":"additional","affiliation":[{"name":"Federica Grosso, Azienda Ospedaliera SS Antonio e Biagio General Hospital, Alessandria; Silvia Novello and Giorgio Scagliotti, L\u2019universit\u00e0 di Torino, Azienda Sanitaria Ospedale San Luigi Gonzaga, Turin, Italy; Anna K. Nowak, University of Western Australia, Crawley, and Sir Charles Gairdner Hospital, Nedlands, Western Australia; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia; Sanjay Popat, The Royal Marsden Hospital National Health Service ..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ars\u00e8ne Bienvenu","family":"Loemb\u00e9","sequence":"additional","affiliation":[{"name":"Federica Grosso, Azienda Ospedaliera SS Antonio e Biagio General Hospital, Alessandria; Silvia Novello and Giorgio Scagliotti, L\u2019universit\u00e0 di Torino, Azienda Sanitaria Ospedale San Luigi Gonzaga, Turin, Italy; Anna K. Nowak, University of Western Australia, Crawley, and Sir Charles Gairdner Hospital, Nedlands, Western Australia; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia; Sanjay Popat, The Royal Marsden Hospital National Health Service ..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Barrueco","sequence":"additional","affiliation":[{"name":"Federica Grosso, Azienda Ospedaliera SS Antonio e Biagio General Hospital, Alessandria; Silvia Novello and Giorgio Scagliotti, L\u2019universit\u00e0 di Torino, Azienda Sanitaria Ospedale San Luigi Gonzaga, Turin, Italy; Anna K. Nowak, University of Western Australia, Crawley, and Sir Charles Gairdner Hospital, Nedlands, Western Australia; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia; Sanjay Popat, The Royal Marsden Hospital National Health Service ..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nassim","family":"Morsli","sequence":"additional","affiliation":[{"name":"Federica Grosso, Azienda Ospedaliera SS Antonio e Biagio General Hospital, Alessandria; Silvia Novello and Giorgio Scagliotti, L\u2019universit\u00e0 di Torino, Azienda Sanitaria Ospedale San Luigi Gonzaga, Turin, Italy; Anna K. Nowak, University of Western Australia, Crawley, and Sir Charles Gairdner Hospital, Nedlands, Western Australia; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia; Sanjay Popat, The Royal Marsden Hospital National Health Service ..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Scagliotti","sequence":"additional","affiliation":[{"name":"Federica Grosso, Azienda Ospedaliera SS Antonio e Biagio General Hospital, Alessandria; Silvia Novello and Giorgio Scagliotti, L\u2019universit\u00e0 di Torino, Azienda Sanitaria Ospedale San Luigi Gonzaga, Turin, Italy; Anna K. Nowak, University of Western Australia, Crawley, and Sir Charles Gairdner Hospital, Nedlands, Western Australia; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia; Sanjay Popat, The Royal Marsden Hospital National Health Service ..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0145039"},{"key":"B2","first-page":"491","volume":"1","author":"Robinson BM","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.04.028"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00007014"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01238-6"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv199"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.136"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318229586e"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31825f22ee"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181ec18db"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318248242c"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2016.1244008"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S78805"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-6307"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/path.824"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050152"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10996"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/dc.20767"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-07-0052"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.126"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-004-3150-2"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr596"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv286"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70586-2"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2944"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.440"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh059"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2014.02.005"},{"key":"B29","unstructured":"Laszlo V, Ozsar J, Klikovits T, et al: Preclinical investigation of the therapeutic potential of nintedanib in malignant pleural mesothelioma. 13th International Conference of the International Mesothelioma Interest Group, Birmingham, United Kingdom, May 1-4, 2016 (abstr)"},{"key":"B30","unstructured":"Lakatos D, Hegedus B, Laszlo V, et al: Nintedanib-induced motility response in mesothelioma cells. Poster presented at the Semmelweis Symposium: Molecular Oncology: from bench to bedside. Budapest, Hungary, November 5-6, 2015"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00366-6"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2217\/lmt.15.33"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0121"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2017.72.9012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T04:05:15Z","timestamp":1653797115000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2017.72.9012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,1]]},"references-count":33,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2017,11,1]]}},"alternative-id":["10.1200\/JCO.2017.72.9012"],"URL":"https:\/\/doi.org\/10.1200\/jco.2017.72.9012","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.731077668.793551910","asserted-by":"object"}]},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,1]]},"assertion":[{"value":"2017-09-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}